Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 3/2012

01-03-2012 | Gynecologic Oncology

Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate

Authors: Elham Shirali, Fariba Yarandi, Zahra Eftekhar, Hadi Shojaei, Zahra Khazaeipour

Published in: Archives of Gynecology and Obstetrics | Issue 3/2012

Login to get access

Abstract

Objective

The most effective treatment of well-differentiated endometrial carcinoma is surgery. The aim of this study is the evaluation of megestrol acetate on young patients with well-differentiated endometrial cancer who wish to preserve their fertility, with regard to the receptors.

Methods

16 patients were treated initially with 160 mg/d of megestrol acetate and continued with 320 mg/d for non-responsive cases. All patients followed with FD&C and hysteroscopy. The responsive patients were referred to IVF group.

Results

Response rate to hormonal therapy was 10/16 (62.5%). The mean time of responding was 7.5 months. Other six (37.5%) patients underwent total abdominal hysterectomy (TAH).
Of 10 patients who responded to hormonal therapy, one exited of the study because of her husband’s infertility. Two patients are under IVF. Three patients did not get pregnant and four patients became pregnant and finally underwent TAH.
All patients had progesterone receptors. Only one patient lacked estrogen receptors; who also responded to treatment.

Conclusion

Progestins treatment of these patients who want to have child may be useful, but close long-term follow-up is necessary. The evaluation of estrogen and progesterone receptors assay may be useful in predicting response to the treatment.
Literature
1.
go back to reference Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC (2008) Current issues in the management of endometrial cancer. Mayo Clin Proc 83(1):97–112 (review)PubMedCrossRef Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC (2008) Current issues in the management of endometrial cancer. Mayo Clin Proc 83(1):97–112 (review)PubMedCrossRef
2.
go back to reference Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95:133–138PubMedCrossRef Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95:133–138PubMedCrossRef
3.
go back to reference Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial. Cancer risk Br J Cancer 57(2):205–212 Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial. Cancer risk Br J Cancer 57(2):205–212
4.
go back to reference Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV Jr, Le Marchand L, Levine DA, Liang X, Lissowska J, Lurie G, McGrath M, Narod SA, Rebbeck TR, Ursin G, Weiss NS, Xiang YB, Yang HP, Zheng W, Olson SH (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18(1):242–247PubMedCrossRef Setiawan VW, Doherty JA, Shu XO, Akbari MR, Chen C, De Vivo I, Demichele A, Garcia-Closas M, Goodman MT, Haiman CA, Hankinson SE, Henderson BE, Horn-Ross PL, Lacey JV Jr, Le Marchand L, Levine DA, Liang X, Lissowska J, Lurie G, McGrath M, Narod SA, Rebbeck TR, Ursin G, Weiss NS, Xiang YB, Yang HP, Zheng W, Olson SH (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18(1):242–247PubMedCrossRef
5.
go back to reference Frumovitz M, Gershenson DM (2006) Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 6:27–32PubMedCrossRef Frumovitz M, Gershenson DM (2006) Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 6:27–32PubMedCrossRef
6.
go back to reference Boing C, Kimmig R (2006) Fertility-preserving treatment in young women with endometrial cancer. Gynakol Geburtshilfliche Rundsch 46:25–33PubMedCrossRef Boing C, Kimmig R (2006) Fertility-preserving treatment in young women with endometrial cancer. Gynakol Geburtshilfliche Rundsch 46:25–33PubMedCrossRef
7.
go back to reference Podczaski E, Mortel R (2001) Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 15:469–489PubMedCrossRef Podczaski E, Mortel R (2001) Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol 15:469–489PubMedCrossRef
8.
go back to reference Yang YC, Wu CC, Chen CP, Chang CL, Wang KL (2005) Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 99:287–293PubMedCrossRef Yang YC, Wu CC, Chen CP, Chang CL, Wang KL (2005) Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol 99:287–293PubMedCrossRef
9.
go back to reference Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249–252PubMedCrossRef Eftekhar Z, Izadi-Mood N, Yarandi F, Shojaei H, Rezaei Z, Mohagheghi S (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249–252PubMedCrossRef
10.
go back to reference Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79:320–327PubMedCrossRef Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79:320–327PubMedCrossRef
11.
go back to reference Yahata T, Fujita K, Aoki Y, Tanaka K (2006) Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21(4):1070–1075. Epub 2005 Dec 16. PubMed PMID: 16361282 Yahata T, Fujita K, Aoki Y, Tanaka K (2006) Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod 21(4):1070–1075. Epub 2005 Dec 16. PubMed PMID: 16361282
12.
go back to reference Zivanovic O, Carter J, Kauff ND, Barakat RR (2009) A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115(3):504–509. (Epub 2009 Sep 15) Zivanovic O, Carter J, Kauff ND, Barakat RR (2009) A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol 115(3):504–509. (Epub 2009 Sep 15)
13.
go back to reference Lai CH, Huang HJ (2006) The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18(1):29–34 Lai CH, Huang HJ (2006) The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 18(1):29–34
15.
go back to reference Ota T, Yoshida M, Kimura M, Kinoshita K (2005) Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15:657–662PubMedCrossRef Ota T, Yoshida M, Kimura M, Kinoshita K (2005) Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15:657–662PubMedCrossRef
16.
go back to reference Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T (2005) Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Bjog 112:317–320PubMedCrossRef Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T (2005) Outcome of fertility-preserving treatment in young women with endometrial carcinomas. Bjog 112:317–320PubMedCrossRef
17.
go back to reference Mousavi AS, Behtash N, Karimi Zarchi M, Modarres Gilani M, Ghaemmaghami F (2007) Fertility preservation in young women with endometrial carcinoma; report of three cases. Tehran Univ Med J 65(2):82–87 Mousavi AS, Behtash N, Karimi Zarchi M, Modarres Gilani M, Ghaemmaghami F (2007) Fertility preservation in young women with endometrial carcinoma; report of three cases. Tehran Univ Med J 65(2):82–87
Metadata
Title
Pregnancy outcome in patients with stage 1a endometrial adenocarcinoma, who conservatively treated with megestrol acetate
Authors
Elham Shirali
Fariba Yarandi
Zahra Eftekhar
Hadi Shojaei
Zahra Khazaeipour
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 3/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-011-2021-8

Other articles of this Issue 3/2012

Archives of Gynecology and Obstetrics 3/2012 Go to the issue